Roth Capital analyst Scott Henry upgraded Inmed Pharmaceuticals (NASDAQ: INM) from Neutral to Buy with a price target of $0.80 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE